for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Synthetic Biologics Inc

SYN.A

Latest Trade

0.46USD

Change

0.00(+0.66%)

Volume

13,153

Today's Range

0.44

 - 

0.46

52 Week Range

0.25

 - 

0.75

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
0.45
Open
0.45
Volume
13,153
3M AVG Volume
13.12
Today's High
0.46
Today's Low
0.44
52 Week High
0.75
52 Week Low
0.25
Shares Out (MIL)
19.44
Market Cap (MIL)
8.83
Forward P/E
-0.68
Dividend (Yield %)
--

Latest Developments

More

Synthetic Biologics Reports 2020 Second Quarter Operational Highlights And Financial Results

Synthetic Biologics Announces FDA Clearance Of Investigational New Drug Application For Syn-020 Intestinal Alkaline Phosphatase

Synthetic Biologics Announces Submission Of Ind Application To U.S. FDA For Syn-020 Intestinal Alkaline Phosphatase

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Synthetic Biologics Inc

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and Phase II SYN-010 which reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company also develops SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

Industry

Biotechnology & Drugs

Contact Info

9605 Medical Center Dr Ste 270

ROCKVILLE, MD

20850-6382

United States

+1.734.3327800

https://www.syntheticbiologics.com/

Executive Leadership

Jeffrey J. Kraws

Non-Executive Independent Chairman of the Board

Steven A. Shallcross

Chief Executive Officer, Chief Financial Officer, Director

Scott L. Tarriff

Independent Director

Jeffrey Alan Wolf

Independent Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2020(E)

0.0K
EPS (USD)

2017

-6.300

2018

-2.140

2019

-0.930

2020(E)

-0.670
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-88.33
Return on Equity (TTM)
-84.38

Latest News

Latest News

BRIEF-Synthetic Biologics Announces Submission Of Ind Application To U.S. FDA For Syn-020 Intestinal Alkaline Phosphatase

* SYNTHETIC BIOLOGICS ANNOUNCES SUBMISSION OF IND APPLICATION TO U.S. FDA FOR SYN-020 INTESTINAL ALKALINE PHOSPHATASE

BRIEF-Synthetic Biologics Enters Option To License Intellectual Property For Use Of SYN-020 For Age-Related Metabolic, Inflammatory Diseases

* SYNTHETIC BIOLOGICS ENTERS OPTION TO LICENSE INTELLECTUAL PROPERTY FOR USE OF SYN-020 TO TREAT, PREVENT AGE-RELATED METABOLIC AND INFLAMMATORY DISEASES Source text for Eikon: Further company coverage:

BRIEF-Synthetic Biologics Reports Qtrly Loss Per Share $0.20

* SYNTHETIC BIOLOGICS REPORTS 2020 FIRST QUARTER OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS

BRIEF-Synthetic Biologics Reports Qtrly Loss Per Share $0.98

* SYNTHETIC BIOLOGICS REPORTS 2019 YEAR END OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS

BRIEF-Synthetic Biologics Announces Acceptance Of Compliance Plan By NYSE American

* SYNTHETIC BIOLOGICS ANNOUNCES ACCEPTANCE OF COMPLIANCE PLAN BY NYSE AMERICAN Source text for Eikon: Further company coverage:

BRIEF-Synthetic Biologics Reports Qtrly Loss Per Share $0.02

* SYNTHETIC BIOLOGICS REPORTS FIRST QUARTER 2018 OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS

BRIEF-Synthetic Biologics Files For Mixed Shelf Of Up To $200 Mln

* SYNTHETIC BIOLOGICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING Source text: (https://bit.ly/2rqOJxd) Further company coverage:

BRIEF-Synthetic Biologics Provides Update On Development Of Syn-004 (Ribaxamase

* SYNTHETIC BIOLOGICS PROVIDES UPDATE ON DEVELOPMENT OF SYN-004 (RIBAXAMASE), FOR THE PREVENTION OF C. DIFFICILE INFECTION

BRIEF-Synthetic Biologics Cash Equivalents On Dec 31, 2017 $17.1 Mln

* SYNTHETIC BIOLOGICS REPORTS 2017 YEAR END OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS

BRIEF-Synthetic Biologics Says CFO Steve Shallcross Has Been Named Interim CEO To Succeed Jeff Riley

* SYNTHETIC BIOLOGICS INC - STEVE SHALLCROSS, CO'S CHIEF FINANCIAL OFFICER, HAS BEEN NAMED INTERIM CEO TO SUCCEED JEFF RILEY

BRIEF-Synthetic Biologics reports Q3 2017 ‍net loss per share of $0.14

* Synthetic Biologics reports third quarter 2017 operational highlights and financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up